MoonLake's Efficacy Claims Face Legal Challenges Amid 90% Stock Drop

Recent Developments Regarding MoonLake's SLK Claims

MoonLake Immunotherapeutics, Inc. (NASDAQ: MLTX) recently faced a staggering 90% drop in its stock value. Following the decline, global plaintiffs' rights law firm Hagens Berman highlighted several critical issues with the company's claims regarding its SLK candidate, particularly in comparison to the established drug BIMZELX. The firm is urging investors to act before the December 15, 2025, deadline for appointment as lead plaintiff in a securities class action lawsuit against the company.

The Core Issues Under Review

The crux of the allegations lies in the assertion that MoonLake might have misrepresented critical data about SLK's performance in clinical trials, notably in the Phase 3 VELA trials. Investors are concerned about whether the company's optimistic statements about SLK's Nanobody structure truly reflected the clinical data and its marketed advantages.

1. Allegations of Molecular Target Deception

Hagens Berman claims that MoonLake failed to disclose a significant detail: SLK and BIMZELX target the same protein, interleukin-17 (IL-17). This revelation raises questions about SLK's competitive differentiation in the market, particularly when entering a space contested by existing therapies. The firm alleges this oversight may have led to inflated expectations among investors.

2. Misleading Claims Regarding Nanobody Efficacy

Furthermore, MoonLake touted the unique Nanobody structure of SLK as a key factor that would provide superior clinical outcomes. However, analysts are investigating whether the data from the VELA trials ever substantiated claims of its efficacy, given that initial results did not demonstrate a significant clinical advantage over existing treatments.

Impact on Investors

The fallout from this situation has been severe, with shares plummeting from $61.99 to $6.24, reflecting a massive financial loss for shareholders. Hagens Berman emphasizes the potential for investors to seek damages if it is proven that MoonLake's actions constituted wrongful acts during the defined Class Period, which ranges from March 10, 2024, to September 29, 2025.

Next Steps for Investors

Reed Kathrein, a partner at Hagens Berman, urges affected investors to come forward promptly. The firm boasts a strong track record of recovering over $2.9 billion for those prejudiced by corporate misdemeanors, and Kathrein is actively advising investors to understand their rights in light of these allegations.

Opportunities for Whistleblowers

Moreover, whistleblowers with non-public information concerning MoonLake's operations may consider leveraging the SEC Whistleblower program. This initiative offers substantial rewards for individuals providing crucial insights that could aid regulatory recovery efforts.

Conclusion

MoonLake stands at a critical juncture as it faces potential legal repercussions from both investors and regulatory agencies. The unfolding events have not only impacted the financial standing of many investors but also bring to light the importance of transparency and accountability in the biotech sector. As the situation develops, all eyes remain on the company's response and the actions taken by those seeking justice for their losses.

For further inquiries or to discuss potential claims, shareholders can reach out to Hagens Berman through their dedicated contact channels or visit the law firm's website for more information. The deadline for filing claims is rapidly approaching, making timely action essential for wronged investors.